We’ll be hosting Clinical Trial Design webinars in 2023! Follow us to be kept up to date. 📊🧑🏻💻
Joined June 2022
- Tweets 111
- Following 64
- Followers 88
- Likes 193
19 Photos and videos
APODDC retweeted
26 Jun 2025
📢 #Happy to share w/ #LCSM community! After 3 years of work, we are pleased to share our #cost_effectiveness modelling for #lungcancer 🫁 #screening 🏥📸 in both #high-risk populations determined by both #smoking & #non-smoking risk factors e.g. family history for an entire community.
Taking #hongkong 🇭🇰 as an example of our #EastAsia region w/ specific lung cancer #epidemiology and #molecularcharacteristics, we have shown that #ICER for high risk individuals based on factors not associated with smoking is even lower.
This is the first study of modelling for an entire health system catering for both high risk groups. This calls for #government & other #stakeholders to push forward #territorywide #lungcancer screening for ALL #highrisk individuals - regardless of smoking history.
Further details can be found here: jtocrr.org/article/S2666-364…
@CarlosWongHKU @mollylisc @CUHKMedicine @hkumed @HKU_D24H @IASLC @APCLC_2023 @apoddc @LungPolicy #NELSON #TALENT #PublicHealth
2
9
27
2,521
APODDC retweeted
13 Apr 2025
Safety of tarlatamab with 6-8h outpatient vs 48-h inpatient monitoring during C1: DeLLphi-300 ph1 substudy in @ESMO_Open. Outpatient monitoring feasible, same CRS rate, most managed w/o hospitalization/ER visit. Anticipate&monitor AEs in educated pts is🔑. esmoopen.com/article/S2059-7…
1
12
33
3,683
APODDC retweeted
7 Apr 2025
Newly published ESMO recommendations provide roadmap for the implementation of molecular tumour boards in clinical practice.
Discover the key focus areas to optimise #PrecisionOncology
Read via #ESMODailyReporter: ow.ly/mexL50VvtUM
@BenWestphalen @Annals_Oncology
4
28
58
6,189
APODDC retweeted
22 Mar 2025
Wonderful crew of @myESMO #ESMORarecancer25 #YOCasesDiscussion session! Definitely not-so-young oncologists including #myself are also welcome.
Great cases discussed and thanks everyone for contributing to lively discussions.
@pawel_sobczuk @DrLizConnolly @Robertasanfili @RobinL_Jones @haileykcarroll and many others. #sarcoma #CTOSTweeTOS
1
5
37
1,232
APODDC retweeted
14 Mar 2025
It's pleasure coauthoring this @Cancer_Cell commentary with 2 talented drug development fellows #gregoire marret and #mercedes herrera @pmcancercentre - "Turning the Kaleidoscope: Innovations shaping the future of clinical trials design"
authors.elsevier.com/a/1kljp…
1
32
111
10,753
APODDC retweeted
16 Mar 2025
🔥 @JCO_ASCO 🆙
✅LIBRETTO-001 final: Selpercatinib in RET Fusion–Positive Non–Small Cell Lung Cancer
🎯mOS 47.6 (pretreated pts), not reached (treatment-naïve)
👥 @GautschiOliver
#LCSM @OncoAlert
12 Mar 2025
Selpercatinib in RET Fusion–Positive Non–Small Cell Lung Cancer #NSCLC 🫁 : Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial
buff.ly/YlqitQJ
This phase I/II study evaluating selpercatinib in RET fusion-positive non–small cell #Lungancer (NSCLC) saw Final results with durable efficacy, an objective response rate (ORR) of 62% in patients who had prior platinum-based chemotherapy and 83% in treatment-naïve patients. The duration of response (DoR) was 31.6 months and 20.3 months, respectively, and progression-free survival (PFS) was 26.2 months for pretreated and 22.0 months for treatment-naïve patients. At 3 years, 57% of pretreated and 66% of treatment-naïve patients were alive. Selpercatinib also demonstrated an 85% ORR in patients with CNS metastases.
@GautschiOliver
@bensolomon1
@herbloong
@geoff_oxnard
@alexdrilon
1
16
51
6,109
APODDC retweeted
16 Feb 2025
Delighted to share our review paper on ADCs in NSCLC with AGA is out! Very timely given the anticipated data readouts this year. Such an honour to be a part of this awesome team, special thanks to @g_mountzios and @JordiRemon for leading this 🙌🏻
16 Feb 2025
Biomarker-selected or biomarker-agnostic ADCs for oncogene-addicted #NSCLC❓
💡Just out in @myESMO #CancerTreatmentReviews a comprehensive overview on current landscape, challenges and perspectives
Grateful to work with a global amazing team, including @stephanieplsaw @HendriksLizza @JessicaMenis Tina Cascone @ogarrieta @DrJNaidoo @Alfdoc2 @peters_solange and senior author @JordiRemon
Link to the Review:👇
doi.org/10.1016/j.ctrv.2025.…
3
19
64
5,421
APODDC retweeted
12 Nov 2024
It's ok at #CTOS2024 to drag me to your poster to pitch your science for Clinical Cancer Research, it the most inspiring thing i get to do!!
2
4
50
1,915
APODDC retweeted
29 Oct 2024
Phase 2 Study: Trametinib Treatment of Epithelioid Hemangioendothelioma. bit.ly/40pDRBc
3
8
1,713
APODDC retweeted
19 Oct 2024
Thanks @drkiwicj @drkiwikate @anmwongNZ @cameroncologist #DaisyMak (who needs to get on Twitter! 😆) & all my other 🇳🇿 #oncology friends @NzsOncology for your invitation & hospitality. Amazing talks & discussions throughout the conference. Perfect forum to build collaborations.
@ASCO #InternationalAffairsCommittee @IASLC #LCSM #Sarcoma @CUHKMedicine #CUHKSarcoma @apoddc @APCLC_2023 #precisiononcology @OncoAlert
18 Oct 2024
What a privilege to have an academic of the quality of @herbloong speaking at @NzsOncology on precision oncology. Kia Ora Herbert!
3
22
1,539
APODDC retweeted
18 Oct 2024
Thank you superstar @herbloong for being a keynote speaker @NzsOncology
Timely discussions on accessibility/ cost savings for #PrecisionOncology
Need personalise a model for 🇳🇿 too!
@apoddc @TeWhatuOra @cancer_agency
2
2
20
558
APODDC retweeted
23 Sep 2024
Thank you @jeanyvesblay for your excellent talk at the @cddf_eu - @EORTC workshop #RareCancers
You last slides summarized it so well
3
19
799
APODDC retweeted
25 Jul 2024
Thanks @drdgoldstein for coming all the way from 🇮🇱 to 🇭🇰 to share insights and experiences in #pharmacoeconomics. Organised by #ProfVivianLee and colleagues of @cuhkpharmacy Very engaged workshop together with stakeholders from #academia, #industry, #patientsrepresentatives and the #HospitalAuthority @CUHKMedicine @hkumed
1
5
23
1,439
📢Announcement: Join us at our 1st #APODDCForum2024 where we discuss about the Regulatory Harmonisation for Oncology Clinical Trials & Therapeutics Registration in the APAC Region📷 Sign up now via lnkd.in/gDPsHNib!📧 More details on our LinkedIn Page!
146
APODDC retweeted
20 May 2024
📢 T-28 days to our 6th @CUHKMedicine #CUHKSarcoma Masterclass in #hongkong 🇭🇰! We are looking forward to welcoming #international and #local faculties to our annual event. Congrats to 8 overseas attendees who have been #awarded #travelgrants to #present and #attend this year's course! Details to follow! @saxotomy @irhkch @val_yang @cuhksurgery @CUHKOrtho @ctosociety
1
3
16
1,005
APODDC retweeted
13 May 2024
Truly honored to have been invited to speak on EGFR-mut NSCLC at the National Cancer Center in Singapore by Daniel Tan and his incredible team. Grateful for the opportunity to share insights and collaborate on such an important topic @danieltanmd @SingHealthSG @pankajpanda86 @reggie_hoo @drkevin_chua_lm @stephanieplsaw
1
11
49
2,923
APODDC retweeted
11 May 2024
Congrats @jeanyvesblay & colleagues of #FrenchSarcomaGroup for completing study of #6vs3years of #adjuvant #imatinib 💊i n pts w/ #highrisk #GISTs. Presented at @myESMO @AACR #virtualplenary over last #2days with #specific discussions from #APAC #discussants as well! #CUHKSarcoma #CTOSTweeTOS @saxotomy @GistLab @Liferaftgroup @ctosociety Recordings available on #OncologyPro!
1
7
30
1,947
APODDC retweeted
8 May 2024
#ESMOVirtualPlenary: And straight after the first abstract session tomorrow (9/5), remain connected to discover more promising results on #GIST. 📢 A randomised study of 6 vs 3 years of adjuvant imatinib in pts w/ localised GIST at high risk of relapse. ow.ly/rKAa50Rza70 @jeanyvesblay @hgelderblom @herbloong @saxotomy
8
8
1,798
APODDC retweeted
8 May 2024
Prof Jacky Lam sharing at the @CUHKMedicine Department of Clinical Oncology Academic Meeting on liquid biopsy for early cancer detection
#oncology
2
17
1,521
APODDC retweeted
25 Apr 2024
Kicked off @ASCO #AsiaPacific #RegionalCouncil meeting in #Kuching #Sarawak 🇲🇾 w/ dedicated council members representing our region and #ASCOStaff. Happy to #vett & #deliver specific initiatives which will benefit #oncology landscape in our region. @DrRoselleDG @DrMLChua @DiahMartina2 #InternationalAffairsCommittee
25 Apr 2024
Kudos to the team! Has been part of this amazing team since the beginning in 2019, it’s very encouraging to see where it leads us now. Thankyou @ASCO APAC Regional Council, Pfizer, and Sarawak Gen Hospital team! Great leadership @DrMLChua !
@DrRoselleDG @herbloong @drkiwikate
3
15
1,153